Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05753384 | Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System | active not recruiting | Phase 3 | 170 | Poitiers University HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 |
| clinicaltrials |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN CLL-321) | active not recruiting | Phase 3 | 238 | Loxo Oncology, Inc.INDUSTRY | 24 | Apr 24, 2026 | clinicaltrials |
| NCT04829539 | Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment(BBT-II) | active not recruiting | Phase 3 | 400 | University of Rochester NCORP Research BaseOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 494 | GlaxoSmithKlineINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 72 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations(AVANZAR) | active not recruiting | Phase 3 | 1,350 | AstraZenecaINDUSTRY | 23 | Apr 22, 2026 | clinicaltrials |
| NCT03927027 | Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection | active not recruiting | Phase 3 | 534 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL(PD1-VEN-CAG) | active not recruiting | Phase 3 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | active not recruiting | Phase 3 | 838 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05780567 | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | active not recruiting | Phase 3 | 1,946 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma(LEDA) | active not recruiting | Phase 3 | 109 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 17, 2026 | clinicaltrials |
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | active not recruiting | Phase 3 | 386 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06382129 | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | active not recruiting | Phase 3 | 698 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06500026 | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | active not recruiting | Phase 3 | 722 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01266044 | Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | active not recruiting | Phase 3 | 435 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 16, 2026 | clinicaltrials |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant(MagnetisMM-7) | active not recruiting | Phase 3 | 854 | PfizerINDUSTRY | 27 | Apr 16, 2026 | clinicaltrials |
| NCT03637816 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor(FINER) | active not recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-9) | active not recruiting | Phase 3 | 614 | Janssen Research & Development, LLCINDUSTRY | 24 | Apr 13, 2026 | clinicaltrials |
| NCT04547049 | A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies | active not recruiting | Phase 3 | 232 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis(SENTRY) | active not recruiting | Phase 3 | 353 | Karyopharm Therapeutics IncINDUSTRY | 20 | Apr 9, 2026 | clinicaltrials |
| NCT06935409 | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | active not recruiting | Phase 3 | 117 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03772028 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(OVHIPEC-2) | active not recruiting | Phase 3 | 538 | The Netherlands Cancer InstituteOTHER | 7 | Apr 8, 2026 | clinicaltrials |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-4) | active not recruiting | Phase 3 | 379 | GenmabINDUSTRY | 28 | Apr 8, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(EXCALIBER-RRMM) | active not recruiting | Phase 3 | 939 | CelgeneINDUSTRY | 31 | Apr 3, 2026 | clinicaltrials |
| NCT01349881 | S0820, Adenoma and Second Primary Prevention Trial(PACES) | active not recruiting | Phase 3 | 354 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04851613 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | active not recruiting | Phase 3 | 256 | Laekna LimitedINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer(EMBER-4) | active not recruiting | Phase 3 | 8,000 | Eli Lilly and CompanyINDUSTRY | 31 | Apr 2, 2026 | clinicaltrials |
| NCT03315364 | Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy(OPTIMAL) | active not recruiting | Phase 2 / Phase 3 | 549 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 5 | Apr 1, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT06430866 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)(Eucalyptus) | active not recruiting | Phase 3 | 163 | AmgenINDUSTRY | 18 | Apr 1, 2026 | clinicaltrials |
| NCT03519048 | Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma(SURVEILL'ORL) | active not recruiting | Phase 3 | 197 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03663725 | Treatment Intensification With Temozolomide in Adults With a Glioblastoma(StrateGlio) | active not recruiting | Phase 3 | 486 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | active not recruiting | Phase 3 | 354 | TakedaINDUSTRY | 24 | Mar 30, 2026 | clinicaltrials |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 3 | 415 | Regeneron PharmaceuticalsINDUSTRY | 16 | Mar 27, 2026 | clinicaltrials |
| NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations(SELVA) | active not recruiting | Phase 3 | 51 | Palvella Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05678322 | Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy | active not recruiting | Phase 3 | 26 | NYU Langone HealthOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases(CAIRO6) | active not recruiting | Phase 2 / Phase 3 | 358 | Koen RoversOTHER | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT03091660 | S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 1,000 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor(MOTION) | active not recruiting | Phase 3 | 123 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Mar 20, 2026 | clinicaltrials |
| NCT02089100 | Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer(STEREO-SEIN) | active not recruiting | Phase 3 | 154 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 27, 2026source: clinicaltrials